wuhan
china
prevent
revers
cytokin
storm
may
key
save
patient
sever
pneumonia
mesenchym
stem
cell
msc
shown
possess
comprehens
power
immunomodulatori
function
studi
aim
investig
whether
msc
transplant
improv
outcom
enrol
patient
pneumonia
clinic
outcom
well
chang
inflammatori
immun
function
level
advers
effect
enrol
patient
assess
day
msc
inject
msc
could
cure
significantli
improv
function
outcom
seven
patient
without
observ
advers
effect
pulmonari
function
symptom
seven
patient
significantli
improv
day
msc
transplant
among
two
common
one
sever
patient
recov
discharg
day
treatment
treatment
peripher
lymphocyt
increas
creactiv
protein
decreas
overactiv
cytokinesecret
immun
cell
cell
cell
nk
cell
disappear
day
addit
group
mid
regulatori
dc
cell
popul
dramat
increas
meanwhil
level
significantli
decreas
increas
msc
treatment
group
compar
placebo
control
group
furthermor
gene
express
profil
show
msc
indic
msc
free
infect
thu
intraven
transplant
msc
safe
effect
treatment
patient
pneumonia
especi
patient
critic
sever
condit
novel
coronaviru
diseas
grown
global
public
health
emerg
sinc
patient
first
detect
wuhan
china
decemb
sinc
number
confirm
patient
sharpli
increas
china
also
worldwid
includ
germani
south
korea
vietnam
singapor
itali
usa
current
specif
drug
vaccin
avail
cure
patient
infect
henc
larg
unmet
need
safe
effect
treatment
infect
patient
especi
sever
case
sever
report
demonstr
first
step
pathogenesi
viru
specif
recogn
angiotensin
convert
enzym
receptor
spike
protein
cell
infect
like
addit
research
team
germani
reveal
cellular
serin
proteas
spike
protein
prime
also
essenti
host
cell
entri
spread
like
coronaviru
ie
unfortun
receptor
wide
distribut
human
cell
surfac
especi
alveolar
type
ii
cell
capillari
endothelium
cell
highli
express
howev
bone
marrow
lymph
node
thymu
spleen
immun
cell
b
lymphocyt
macrophag
consist
neg
find
suggest
immunolog
therapi
may
use
treat
infect
patient
howev
immunomodulatori
capac
may
strong
enough
one
two
immun
factor
use
viru
stimul
terribl
cytokin
storm
lung
gscf
follow
edema
dysfunct
air
exchang
acut
respiratori
distress
syndrom
acut
cardiac
injuri
secondari
infect
may
lead
death
therefor
avoid
cytokin
storm
may
key
treatment
infect
patient
msc
owe
power
immunomodulatori
abil
may
benefici
effect
prevent
attenu
cytokin
storm
msc
wide
use
cellbas
therapi
basic
research
clinic
trial
safeti
effect
clearli
document
mani
clinic
trial
especi
immunemedi
inflammatori
diseas
graft
versushost
diseas
gvhd
system
lypu
erythematosu
sle
msc
play
posit
role
mainli
two
way
name
immunomodulatori
effect
differenti
abil
msc
secret
mani
type
cytokin
paracrin
secret
make
direct
interact
immun
cell
lead
immunomodul
immunomodulatori
effect
msc
trigger
activ
tlr
receptor
msc
stimul
pathogenassoci
molecul
lp
doublestrand
rna
viru
like
conduct
msc
transplant
pilot
studi
explor
therapeut
potenti
infect
patient
addit
also
explor
underli
mechan
use
genom
high
throughput
rna
sequenc
cluster
analysi
msc
mass
cytometri
pilot
trial
intraven
msc
transplant
perform
seven
patient
infect
pneumonia
studi
conduct
beij
youan
hospit
capit
medic
univers
china
approv
ethic
committe
hospit
safeti
scientif
valid
studi
clinic
trial
mesenchym
stem
cell
treatment
pneumon
caus
novel
coronaviru
shanghai
univers
pumc
review
scientif
committe
intern
societi
age
diseas
isoad
issu
chines
clinic
trial
registri
patient
enrol
jan
jan
enrol
patient
confirm
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
assay
rna
chines
center
diseas
control
prevent
use
protocol
describ
previous
sequenc
follow
forward
primer
revers
primer
probe
initi
enrol
patient
age
year
accord
guidanc
nation
health
commiss
china
tabl
improv
sign
observ
standard
treatment
patient
would
suggest
join
polit
studi
patient
inelig
diagnos
kind
cancer
doctor
declar
situat
belong
critic
sever
condit
exclud
patient
particip
clinic
trial
particip
clinic
trial
within
month
clinic
grade
msc
suppli
free
shanghai
univers
qingdao
coorient
watson
biotechnolog
group
co
ltd
institut
basic
medic
scienc
chines
academi
medic
scienc
cell
product
certifi
nation
institut
food
drug
control
china
author
number
intraven
drip
msc
suspend
ml
normal
salin
total
number
transplant
cell
calcul
cell
per
kilogram
weight
window
period
cell
transplant
defin
time
symptom
orand
sign
still
get
wors
even
expect
treatment
conduct
inject
perform
forti
minut
speed
drop
per
minut
patient
assess
investig
observ
receiv
investig
product
clinic
laboratori
radiolog
outcom
record
certifi
train
group
doctor
detail
record
includ
primari
safeti
data
infusion
allerg
reaction
secondari
infect
lifethreaten
advers
event
primari
efficaci
data
level
cytokin
variat
level
creactiv
protein
plasma
oxygen
satur
secondari
efficaci
outcom
mainli
includ
total
lymphocyt
count
subpopul
chest
ct
respiratori
rate
patient
symptom
especi
fever
short
breath
addit
therapeut
measur
ie
antivir
medicin
respiratori
support
outcom
also
examin
mimic
interact
medic
imag
control
system
materialis
belgium
use
evalu
chest
ct
data
analysi
mass
cytometri
peripher
blood
mononuclear
cell
describ
supplementari
analysi
x
rnaseq
survey
describ
supplementari
data
analyz
spss
softwar
spss
differ
two
group
assess
use
unpair
twotail
test
data
involv
two
group
assess
analysi
varianc
anova
p
valu
indic
statist
signific
studi
conduct
jan
feb
seven
confirm
patient
includ
critic
sever
type
patient
sever
type
patient
common
type
patient
enrol
msc
transplant
three
sever
type
enrol
placebo
control
timepoint
msc
transplant
patient
shown
figur
gener
inform
patient
list
tabl
hitherto
critic
sever
patient
complet
msc
treatment
patient
medic
histori
hypertens
highestlevel
mmhg
record
treatment
inform
patient
collect
msc
transplant
patient
symptom
high
fever
weak
short
breath
low
oxygen
satur
howev
day
transplant
symptom
disappear
patient
oxygen
satur
rose
rest
without
oxygen
uptak
liter
per
minut
addit
acut
infusionrel
allerg
reaction
observ
within
two
hour
transplant
similarli
delay
hypersensit
secondari
infect
detect
treatment
detail
diagnosi
treatment
procedur
critic
sever
patient
shown
supplementari
main
symptom
sign
shown
tabl
immunomodul
function
msc
contribut
main
efficaci
outcom
transplant
msc
show
impress
posit
result
tabl
primari
outcom
critic
sever
patient
plasma
creaction
protein
level
decreas
gl
jan
gl
feb
reach
highest
level
gl
feb
indic
inflamm
statu
allevi
quickli
oxygen
satur
without
supplementari
oxygen
rose
jan
feb
indic
pulmonari
alveoli
regain
airchang
function
secondari
outcom
also
improv
tabl
consid
exampl
critic
sever
patient
lymphopenia
significantli
improv
cell
transplant
patient
isol
hospit
isol
ward
histori
hypertens
blood
pressur
reach
grade
hypertens
feb
biochem
indic
blood
test
show
aspart
aminotransferas
creatin
kinas
activ
myoglobin
increas
sharpli
ul
ul
ngml
respect
indic
sever
damag
liver
myocardium
howev
level
function
biochem
indic
decreas
normal
refer
valu
day
treatment
tabl
figru
sever
patient
regulatori
cell
dc
increas
cell
therapi
especi
critic
sever
patient
figur
moreov
critic
sever
patient
msc
transplant
percentag
overactiv
cell
cell
nk
cell
patient
pbmc
remark
increas
compar
healthi
control
figur
howev
day
msc
transplant
overactiv
cell
nk
cell
nearli
disappear
number
cell
subset
almost
revers
normal
level
especi
mid
dc
popul
normal
healthi
individu
msc
mesenchym
stem
cell
transplant
group
ctrl
placebo
control
group
februari
index
reach
normal
level
name
ul
ul
ngml
respect
respiratori
rate
decreas
normal
rang
day
msc
transplant
fever
short
breath
disappear
day
msc
transplant
chest
ct
imag
show
groundglass
opac
pneumonia
infiltr
larg
reduc
day
msc
transplant
fig
rtpcr
analysi
nucleic
acid
perform
msc
transplant
critic
sever
patient
transplant
jan
day
transplant
feb
nucleic
acid
posit
day
transplant
feb
nucleic
acid
turn
neg
patient
also
turn
neg
nucleic
acid
report
date
investig
profil
immun
system
constitut
msc
transplant
perform
cytof
analyz
immun
cell
patient
peripher
blood
transplant
cytof
reveal
nearli
increas
regulatori
cell
dendrit
cell
dc
two
patient
common
type
patient
sever
patient
regulatori
cell
dc
increas
cell
therapi
especi
critic
sever
patient
notabl
signific
dc
enhanc
observ
placebo
treatment
three
sever
control
patient
moreov
critic
sever
patient
msc
transplant
percentag
cell
cell
nk
cell
patient
pbmc
remark
increas
compar
healthi
control
caus
inflammatori
cytokin
storm
howev
day
msc
transplant
overactiv
cell
nk
cell
nearli
disappear
number
cell
subpopul
almost
restor
normal
level
especi
mid
regulatori
dendrit
cell
popul
fig
intraven
inject
msc
decreas
ratio
serum
proinflammatori
cytokin
msc
treatment
signific
p
meanwhil
increas
ratio
antiinflammatori
p
also
show
remark
msc
treatment
group
serum
level
chemokin
like
growth
factor
vegf
increas
though
significantli
fig
elucid
mechan
underli
mscmediat
protect
infect
patient
perform
x
rnaseq
survey
transplant
msc
x
rnaseq
survey
captur
msc
sequenc
raw
read
total
supplementari
fig
result
reveal
msc
neg
indic
msc
free
infect
moreov
antiinflammatori
trophic
factor
like
hgf
lif
gal
fgf
vegf
egf
bdnf
ngf
highli
express
msc
demonstr
immunomodulatori
function
msc
moreov
spa
spc
highli
express
msc
indic
msc
might
differenti
cell
fig
kegg
pathway
analysi
show
msc
close
involv
antivir
pathway
supplementari
fig
novel
coronaviru
could
enter
host
cell
bind
protein
viral
surfac
cell
surfac
addit
lung
wide
express
human
tissu
includ
heart
liver
kidney
digest
organ
fact
almost
endotheli
cell
smooth
muscl
cell
organ
express
therefor
viru
enter
blood
circul
spread
wide
tissu
organ
express
could
battlefield
novel
coronaviru
immun
cell
explain
infect
icu
patient
suffer
acut
respiratori
distress
syndrom
also
complic
acut
myocardi
injuri
arrhythmia
acut
kidney
injuri
shock
death
multipl
organ
dysfunct
syndrom
fig
moreov
like
affect
older
male
comorbid
result
sever
even
fatal
respiratori
diseas
acut
respiratori
distress
syndrom
like
critic
sever
case
howev
cure
essenti
depend
patient
immun
system
overactiv
immun
system
kill
viru
produc
larg
number
inflammatori
factor
lead
sever
cytokin
storm
suggest
main
reason
organ
damag
may
due
virusinduc
cytokin
storm
older
subject
may
much
easier
affect
due
immunosenesc
scrnaseq
survey
show
msc
best
knowledg
first
time
report
secret
antiinflammatori
factor
prevent
cytokin
storm
natur
immun
accord
mass
cytometri
stream
result
viru
infect
caus
total
function
failur
lymphocyt
even
whole
immun
system
msc
play
vital
immun
modul
role
revers
lymphocyt
subset
mainli
dendrit
cell
previou
studi
show
cocultur
msc
could
decreas
differenti
cdc
human
cell
increas
differenti
pdc
furthermor
induct
regulatori
dendrit
cell
regulatori
dendrit
cell
hsc
also
report
rat
msc
could
also
induc
matur
dendrit
cell
novel
regulatori
dendrit
cell
popul
interact
differ
dendrit
cell
led
shift
immun
system
toward
respons
sever
report
also
focus
lymphopenia
high
level
creactiv
protein
patient
creactiv
protein
biomark
highsensit
inflamm
host
respons
product
cytokin
particularli
secret
cell
howev
mechanist
studi
suggest
creactiv
protein
unlik
target
intervent
creactiv
protein
also
biomark
myocardi
damag
msc
therapi
inhibit
overactiv
immun
system
promot
endogen
repair
improv
microenviron
enter
human
bodi
intraven
infus
part
msc
accumul
lung
could
improv
pulmonari
microenviron
protect
alveolar
epitheli
cell
prevent
pulmonari
fibrosi
improv
lung
function
report
cao
team
level
serum
gscf
icu
patient
higher
normal
patient
cytokin
releas
syndrom
caus
abnorm
activ
immun
cell
deterior
patient
state
may
caus
disabl
function
endotheli
cell
capillari
leakag
mucu
block
lung
final
respiratori
failur
could
caus
even
inflammatori
cytokin
storm
lead
multipl
organ
failur
administr
intraven
inject
msc
significantli
improv
inflamm
situat
sever
patient
due
uniqu
immunosuppress
capac
serum
level
proinflammatori
cytokin
chemokin
reduc
dramat
attract
less
mononuclear
macrophag
fragil
lung
induc
regulatori
dendric
cell
inflammatori
tissu
nich
moreov
increas
vegf
promot
lung
repair
ultim
patient
sever
pneumonia
surviv
worst
condit
enter
recoveri
therefor
fact
transplant
msc
improv
outcom
patient
may
due
regul
inflammatori
respons
promot
tissu
repair
regener
